TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15528909

Group type: EXPERIMENTAL
Intervention: High-dose sodium fluoride dentifrice (2,800 ppm F, high-NaF)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Experimental 0.454% stabilized stannous fluoride with sodium hexametaphosphate dentifrice (SnF2-HMP)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Low-dose sodium fluoride dentifrice (500 ppm F, low-NaF)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Standard 1,100 ppm F sodium fluoride positive control dentifrice
Number of subjects: 955
Study: 11731182

Group type: EXPERIMENTAL
Intervention: Multiple regression model
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Discriminant analysis model
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Clinical and biochemical variables
Number of subjects: 2016
Study: 9563865

Group type: EXPERIMENTAL
Intervention: Propofol (initial bolus 0.1 mg kg(‐1) then 1 mg kg(‐1)h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ondansetron (initial bolus 0.11 mg kg(‐1) then 14 microg kg(‐1)h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7946936

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3429174

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) glucagon
Number of subjects: 435

Group type: COMPARATOR
Intervention: No glucagon (Control)
Number of subjects: 435
Study: 28462577

Group type: EXPERIMENTAL
Intervention: Lode Excalibur Sport
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tacx i-Magic
Number of subjects: 8
Study: 26988811

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 656

Group type: COMPARATOR
Intervention: CTP+CTA
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: NCCT
Number of subjects: 656
Study: 25196321

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil in the morning and at noon over 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 33
Study: 23496025

Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 15
Study: 21832304

Group type: EXPERIMENTAL
Intervention: C+P (carbohydrate with protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: C (carbohydrate without protein)
Number of subjects: 10
Study: 17603048

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg once daily with brief lifestyle modification
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo with brief lifestyle modification
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 42
Study: 17115902

Group type: EXPERIMENTAL
Intervention: HCV therapy
Number of subjects: 0
Study: 12663719

Group type: COMPARATOR
Intervention: Oxaliplatin 130 mg/m² day 1 plus capecitabine 2,000 mg/m²/d days 1 to 14 every 3 weeks (arm A)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m² days 1 and 14 combined with capecitabine 3,500 mg/m² days 1 to 7 and 14 to 21 every 4 weeks (arm B)
Number of subjects: 89
Study: 11045370

Group type: EXPERIMENTAL
Intervention: Philips HP555 electric toothbrush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Philips HP510 electric toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual toothbrush (Jordan V‐shaped, medium)
Number of subjects: 50
Study: 9005676

Group type: EXPERIMENTAL
Intervention: Slit-suction drainage
Number of subjects: 44

Group type: COMPARATOR
Intervention: Redon-suction drainage
Number of subjects: 44
Study: 2148333

Group type: EXPERIMENTAL
Intervention: Total night's sleep deprivation (TSD) under 'conventional' conditions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total night's sleep deprivation (TSD) with patients kept in bed and not permitted to sleep
Number of subjects: 30
Study: 7417369

Group type: COMPARATOR
Intervention: Moderate-fat diet (30% energy from fat, 1/3 PUFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20 energy % PUFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-fat diet (40 energy % fat, 19 energy % PUFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-fat diet (40 energy % fat, 3 energy % PUFA)
Number of subjects: 60
Study: 31909703

Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Typical physical therapy (Control)
Number of subjects: 16
Study: 31655054

Group type: EXPERIMENTAL
Intervention: A-index nomogram
Number of subjects: 672
Study: 31226660

Group type: EXPERIMENTAL
Intervention: Subliminal intragastric infusion of 2.5 g lauric acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Positive emotion induction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 26859547

Group type: EXPERIMENTAL
Intervention: 0.4 μg/kg dexmedetomidine (small dose)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 0.8 μg/kg dexmedetomidine (medium dose)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Normal saline (vehicle control)
Number of subjects: 134
Study: 25305352

Group type: EXPERIMENTAL
Intervention: 1α,25-dihydroxyvitamin D3 (1,25(OH)2D)
Number of subjects: 0
Study: 24078278

Group type: EXPERIMENTAL
Intervention: DA-3031 (1.8, 3.6, 6, or 18 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DA-3031 (3.6 to 6 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Filgrastim (100 μg/m² daily for 5 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DA-3031 and Filgrastim
Number of subjects: 48
Study: 21775759

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling intervention
Number of subjects: 925

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 925
Study: 19420402

Group type: EXPERIMENTAL
Intervention: 18-week physical activity program
Number of subjects: 16
Study: 17012110

Group type: EXPERIMENTAL
Intervention: Serum VEGF levels in PCOS patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Serum bFGF levels in PCOS patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Follicular fluid VEGF and bFGF levels in PCOS patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation of serum bFGF levels with FSH administration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation of follicular fluid bFGF concentrations with mature oocytes
Number of subjects: 52
Study: 12507525

Group type: EXPERIMENTAL
Intervention: Video intervention 'Underage Drinking: A Roll of the Dice' with accompanying discussion guide.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Video intervention 'Underage Drinking: A Roll of the Dice' with follow-up materials.
Number of subjects: 300
Study: 10981170

Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil (angiotensin receptor blocker)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 9387947

Group type: EXPERIMENTAL
Intervention: Forced Oscillation Technique (FOT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Forced Expiratory Volume in one second (FEV1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of dry cold air (IHCA)
Number of subjects: 29
Study: 7963780

Group type: EXPERIMENTAL
Intervention: Hypodermoclysis (HDC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Hypodermoclysis (Control)
Number of subjects: 100
Study: 3298301

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenge treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (calcium lactate tablets)
Number of subjects: 0
Study: 29276123

Group type: EXPERIMENTAL
Intervention: Posterior-Stabilized (PS) device
Number of subjects: 111

Group type: COMPARATOR
Intervention: Condylar-Stabilized (CS) device
Number of subjects: 111
Study: 27983687

Group type: EXPERIMENTAL
Intervention: Whole oat flour (48 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Whole barley flour (48 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Refined wheat flour plus cellulose (control)
Number of subjects: 13
Study: 24034670

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% Magnolia extract
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 94
Study: 22936658

Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy (10 mg or 15 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) with lenalidomide and rhu-EPO (40,000 U/wk)
Number of subjects: 39
Study: 20077491

Group type: EXPERIMENTAL
Intervention: Stokes polarimetry imaging (SPI) system with varying incident polarization angles (IPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dermoscopy and histology images
Number of subjects: 0
Study: 18079083

Group type: EXPERIMENTAL
Intervention: Zinc dietary recommendations derived from factorial calculations
Number of subjects: 0
Study: 15699058

Group type: EXPERIMENTAL
Intervention: Structured warm‐up programme
Number of subjects: 1837

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1837
Study: 12848631

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg b.d.) + Amoxicillin (1000 mg b.d.) (RA group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Rabeprazole (10 mg b.d.) + Amoxicillin (750 mg twice b.d.) + Metronidazole (250 mg b.d.) (RAM group)
Number of subjects: 123
Study: 10641899

Group type: EXPERIMENTAL
Intervention: Vitamin E intervention
Number of subjects: 0
Study: 8963958

Group type: EXPERIMENTAL
Intervention: Systemically effective dose of AII
Number of subjects: 8

Group type: COMPARATOR
Intervention: Systemically ineffective dose of AII
Number of subjects: 8
Study: 1390493

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of a preservative‐free aqueous solution of gentamicin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin containing sodium metabisulphite and disodium edetate as preservatives
Number of subjects: 75

Group type: COMPARATOR
Intervention: No subconjunctival injection (Control Group)
Number of subjects: 75
Study: 3924286

Group type: EXPERIMENTAL
Intervention: Honey in oral rehydration solution
Number of subjects: 0
Study: 29449329

Group type: EXPERIMENTAL
Intervention: niacin‐laropiprant
Number of subjects: 3978

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3978
Study: 27503091

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400 mg/day)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 23647356

Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine digluconate gel (CHX)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (Ca(OH)2)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Chemomechanical preparation with 3% sodium hypochlorite (NaOCl)
Number of subjects: 69
Study: 22882916

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate alone (1 mg; one dose before and two doses after biopsy)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate + ciprofloxacin (250 mg; one dose before and two doses after biopsy)
Number of subjects: 367
Study: 19928700

Group type: EXPERIMENTAL
Intervention: Unilateral rectus recession (7.0 to 7.5 mm for 15 to 20 PD and 8.0 to 8.5 mm for 21 to 25 PD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bilateral rectus recession (5.0 to 5.5 mm for 15 to 20 PD and 6.0 to 6.5 mm for 21 to 25 PD)
Number of subjects: 20
Study: 19025274

Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention (telephone counseling and tailored newsletters)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 320
Study: 16024926

Group type: EXPERIMENTAL
Intervention: High-dose citric acid-based UBT at 14 days after triple therapy
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: High-dose citric acid-based UBT at 7 days after triple therapy
Number of subjects: 233

Group type: COMPARATOR
Intervention: Gold standard UBT at 6 weeks after therapy
Number of subjects: 233
Study: 12601506

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus Cyproheptadine 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg plus Cyproheptadine 4 mg
Number of subjects: 20
Study: 10365576

Group type: EXPERIMENTAL
Intervention: Interferon therapy (interferon-alpha 2b) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 8660081

Group type: EXPERIMENTAL
Intervention: Colestipol (10 g/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 1826048

Group type: EXPERIMENTAL
Intervention: ZOLADEX (3.6 mg every 28 days by subcutaneous injection)
Number of subjects: 67

Group type: COMPARATOR
Intervention: DES (3 mg daily by oral administration)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ZOLADEX
Number of subjects: 67

Group type: COMPARATOR
Intervention: ZOLADEX and DES
Number of subjects: 67
Study: 7134228

Group type: EXPERIMENTAL
Intervention: Aluminium oxide adsorbate vaccines (54, 108, and 216 IU/dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fluid monovalent influenza A/New Jersey/8/76 vaccines (double the antigen content)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aluminium oxide adsorbate vaccines
Number of subjects: 90
Study: 30580144

Group type: EXPERIMENTAL
Intervention: Tempo of audible pedestrian signals (40 bpm, 60 bpm, 120 bpm)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Pitch of audible pedestrian signals (175 Hz, 350 Hz, 700 Hz)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Real crossing scenario with different tempos
Number of subjects: 217
Study: 29883653

Group type: EXPERIMENTAL
Intervention: Automated titanium fasteners
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional hand‐tied knots
Number of subjects: 50
Study: 26739723

Group type: EXPERIMENTAL
Intervention: Self-management programme integrated into stroke rehabilitation
Number of subjects: 78
Study: 25147037

Group type: EXPERIMENTAL
Intervention: Transcatheter patent foramen ovale (PFO) closure using the STARFlex device
Number of subjects: 909

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Index TIA
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Detection of atrial fibrillation after study enrollment
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: RoPE (Risk of Paradoxical Embolism) score ≤5
Number of subjects: 909
Study: 22683038

Group type: COMPARATOR
Intervention: Conventional formula containing lactose (9.6 g/100 kcal) and maltodextrin (1.6 g/100 kcal)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 100% lactose formula (11.2 g/100 kcal)
Number of subjects: 178
Study: 20390984

Group type: EXPERIMENTAL
Intervention: Unmet need for information
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Unmet need for emotional support
Number of subjects: 122
Study: 18537025

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16029995

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 983

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 983

Group type: COMPARATOR
Intervention: Calcium-channel blockers (CCB)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Irbesartan, ACE inhibitors, CCB
Number of subjects: 983
Study: 12173199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine < 20 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine 20-40 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine > 40 min
Number of subjects: 120
Study: 10348261

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel with amifostine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel without amifostine
Number of subjects: 0
Study: 8559949

Group type: EXPERIMENTAL
Intervention: Continuation light treatment until late winter (n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stopped light treatment early during winter (n = 6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuation light treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comorbid avoidant personality
Number of subjects: 20
Study: 2706319

Group type: EXPERIMENTAL
Intervention: Research Suspension (RS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Marketing Suspension (MS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference Oral Solution (SOL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All formulations (MS, RS, SOL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MS and RS
Number of subjects: 24
Study: 29668611

Group type: EXPERIMENTAL
Intervention: Intradermal needle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham intradermal needle
Number of subjects: 40
Study: 28807667

Group type: EXPERIMENTAL
Intervention: C-82
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25892575

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 62
Study: 23179805

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intracorporeal sutures
Number of subjects: 60
Study: 21282590

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Bevacizumab + Irinotecan (BEV+CPT‐11)
Number of subjects: 167
Study: 18454914

Group type: EXPERIMENTAL
Intervention: 3.5% solution of betadine irrigation before final closing of the wound (Group 1)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No betadine irrigation during the intraoperative period (Group 2)
Number of subjects: 162
Study: 16792606

Group type: EXPERIMENTAL
Intervention: 80% supplemental oxygen
Number of subjects: 560
Study: 14599044

Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture
Number of subjects: 0
Study: 10938492

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Perindopril 2.0 mg
Number of subjects: 298
Study: 8737690

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg orally TID for 3 days preoperatively and 300 mg infusion after anesthetic induction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 20
Study: 1559860

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 25
Study: 3933393

Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids (BCAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25% branched chain amino acids (BCAA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 12
Study: 30578542

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (in black women subgroup)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (in black women subgroup)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (in obese women subgroup)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (in obese women subgroup)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 56
Study: 29035099

Group type: EXPERIMENTAL
Intervention: GDF‐15 levels in LVH patients (n=67)
Number of subjects: 302

Group type: COMPARATOR
Intervention: GDF‐15 levels in non-LVH patients (n=172)
Number of subjects: 302

Group type: COMPARATOR
Intervention: GDF‐15 levels in healthy controls (n=63)
Number of subjects: 302
Study: 27283096

Group type: EXPERIMENTAL
Intervention: Technology-integrated weight gain prevention intervention (1-credit academic course and online social networking support)
Number of subjects: 441
Study: 24509273

Group type: EXPERIMENTAL
Intervention: Evolocumab (AMG 145) 140 mg every 2 weeks
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Evolocumab (AMG 145) 420 mg every 4 weeks
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Evolocumab treatment
Number of subjects: 1359
Study: 23156204

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 0
Study: 19960343

Group type: EXPERIMENTAL
Intervention: C allele carriers
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Smoker and ex-smoker individuals
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-smoker NSCLC patients
Number of subjects: 243
Study: 17298834

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 15616296

Group type: EXPERIMENTAL
Intervention: Telavancin 7.5 mg/kg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telavancin 12.5 mg/kg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telavancin 15 mg/kg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telavancin (multiple doses)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telavancin (24 h postinfusion)
Number of subjects: 54
Study: 12062586

Group type: EXPERIMENTAL
Intervention: 300 mg of M. officinalis (Pharmaton)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600 mg of M. officinalis (Pharmaton)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 900 mg of M. officinalis (Pharmaton)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10652673

Group type: EXPERIMENTAL
Intervention: Angio-Seal system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 0
Study: 7548608

Group type: EXPERIMENTAL
Intervention: Modified cellulose membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic membrane (polysulphone)
Number of subjects: 0